Figure 12.1 (a) Charcot changes in the tarso-metatarsal joints with subluxation of the lateral four rays, going laterally, so that the space between the first and second metatarsals is increased…
Figure 2.1 Diagram illustrating the relationship and function of the teams responsible for providing care to people with diabetes and foot complications Multi-disciplinary team (MDT) management is essential to ensure…
Figure 9.1 Pathway for revascularisation of the diabetic foot Choice of Bypass Conduit There are three choices when considering a conduit for bypass surgery. By far the superior choice is…
© Springer-Verlag London 2015Clifford P. Shearman (ed.)Management of Diabetic Foot Complications10.1007/978-1-4471-4525-7_1 1. Foot Complications in Diabetes: The Problem Clifford P. Shearman1 (1) Department of Vascular Surgery, University of Southampton, University Hospital of Southampton NHS Foundation Trust,…
Infection severity Probable pathogen(s) Antibiotic agent Comments Mild (usually treated with oral agent[s]) Staphylococcus aureus (MSSA); Streptococcus spp. Dicloxacillin Requires QID dosing; narrow-spectrum; inexpensive Clindamycinb Usually active against community-associated MRSA,…
Oral agent classes (e.g., denotes other agents in same class available) Biguanides (metformin) Sulphonylureas (e.g., gliclazide) Thiazolidinediones (pioglitazone) Alpha glucosidase inhibitors (acarbose) Meglitinides (e.g., repaglinide) Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g.,…
